ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. As of June 30, 2025, the company has six marketed products (four commercialized directly: AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO; two by collaborators: Leqvio, Qfitlia) and a pipeline of over 20 clinical programs. The company is executing its "Alnylam P 5 x25" strategy to become a top-tier biotech company by the end of 2025.

Key Financial Metrics

Note: Cash and Marketable Securities calculated as sum of Cash and cash equivalents ($1,113,685) and Marketable debt securities ($1,743,900) as of June 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 17% in Q2 2025 and 19% for the six months ended June 30, 2025, compared to the prior year periods. This was primarily driven by a 64% increase in net product revenues.
• Product Performance:
  • AMVUTTRA: Revenues surged 114% in Q2 2025 ($491.9M) compared to Q2 2024 ($230.1M), driven by the March 2025 FDA approval for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and subsequent global approvals.
  • ONPATTRO: Revenues declined 32% in Q2 2025 ($52.5M) due to patient switches to AMVUTTRA.
  • GIVLAARI & OXLUMO: Both showed growth, with GIVLAARI up 30% and OXLUMO up 15% in Q2 2025.
• Collaboration Revenue Decline: Net revenues from collaborations decreased 73% in Q2 2025 ($61.5M) compared to Q2 2024 ($227.3M). This was largely due to the recognition of $185.0 million in revenue from the Regeneron collaboration in Q2 2024 related to the amended C5 License Agreement, which did not recur in 2025.
• Expense Increases:
  • Cost of Goods Sold (COGS): Increased 111% in Q2 2025, primarily due to higher AMVUTTRA sales and associated royalties.
  • R&D Expenses: Increased 10% in Q2 2025, driven by startup activities for Phase 3 trials of zilebesiran and nucresiran.
  • SG&A Expenses: Increased 30% in Q2 2025, attributed to higher compensation costs and marketing investments for the AMVUTTRA ATTR-CM launch.
• Net Loss Expansion: Net loss increased significantly to $66.3M in Q2 2025 from $16.9M in Q2 2024, reflecting the drop in collaboration revenue and increased operating expenses.

Guidance, Outlook, and Risks

• Strategic Outlook: Management aims to achieve sustainable operating profitability by the end of 2025. The company expects collaboration revenues to increase in 2025 driven by the Roche collaboration, and royalty revenues to grow from Leqvio and Qfitlia sales.
• Pipeline Updates:
  • AMVUTTRA: Received approvals for ATTR-CM in the EU, UK, Japan, Brazil, and Colombia in addition to the U.S.
  • Nucresiran: Initiated Phase 3 TRITON-CM trial for ATTR-CM; received FDA Fast Track Designation.
  • Mivelsiran: Presented Phase 1 data for Alzheimer's disease; Phase 2 trial expected to initiate in H2 2025.
  • Zilebesiran: Phase 2 KARDIA-3 results expected in H2 2025; Phase 3 cardiovascular outcomes trial expected to initiate in H2 2025.
• Liquidity: As of June 30, 2025, the company held approximately $2.86 billion in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Regulatory & Clinical: Risks associated with clinical trial failures, regulatory delays, and the partial clinical hold on mivelsiran due to non-clinical toxicology findings.
  • Legal: Ongoing patent infringement litigation against Pfizer and Moderna (recently resulted in judgments of non-infringement, with appeals pending or being evaluated) and a new lawsuit filed by the University of Texas regarding ONPATTRO.
  • Collaboration Dependence: Reliance on partners (Roche, Regeneron, Novartis, Sanofi) for development and commercialization of key assets like Leqvio and Qfitlia.
  • Convertible Notes: $1.04 billion in 1% Convertible Senior Notes due 2027, which may require cash settlement upon conversion or repurchase upon fundamental change.

Investor Verification Checklist

• AMVUTTRA Commercialization: Verify the pace of patient uptake and market share capture for AMVUTTRA in the ATTR-CM indication following recent global approvals.
• Collaboration Milestones: Monitor the timing of the Phase 3 initiation milestone payment from Roche for zilebesiran, which is critical for 2025 revenue targets.
• Regulatory Status of Nucresiran: Track the progress of the TRITON-CM Phase 3 trial and any potential regulatory feedback on the Fast Track designation.
• Legal Proceedings: Review the status of the University of Texas patent infringement lawsuit regarding ONPATTRO and the outcome of appeals in the Pfizer/Moderna cases.
• Profitability Path: Assess the trajectory of SG&A and R&D expenses relative to revenue growth to determine feasibility of the "sustainable operating profitability by end of 2025" target.
• Debt Obligations: Evaluate the company's ability to service or refinance the $1.04 billion convertible debt, particularly in the event of a fundamental change or conversion trigger.